Australia - Inggris - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - conjugated estrogens, quantity: 0.45 mg; bazedoxifene acetate, quantity: 22.56 mg (equivalent: bazedoxifene, qty 20 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; hypromellose; microcrystalline cellulose; hyprolose; macrogol 400; magnesium stearate; sucrose palmitate; ascorbic acid; powdered cellulose; calcium phosphate; sucrose; propylene glycol; purified water; isopropyl alcohol; iron oxide black; titanium dioxide; iron oxide red; polydextrose; povidone; hyetellose; maltitol solution; poloxamer - duavive is indicated for treatment of moderate to severe vasomotor symptoms associated with menopause in women with a uterus.,- duavive should be used for the shortest duration consistent with treatment goals and risks for the individual woman.,- experience in women older than 65 years is limited.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - estradiol, quantity: 1 mg (equivalent: estradiol hemihydrate, qty 1.03 mg); dydrogesterone, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; hypromellose; maize starch; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; ferrosoferric oxide - hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uteri. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest possible effective dose for the shortest duration should be used with the goal being short term use.,hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uterus. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used with the goal being short term use (see dosage and administration and clinical trials). when prescribed solely for the prevention of postmenopausal bone mineral density loss in women, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of femoston should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing( see precautions and dosage and administration).

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol hemihydrate, quantity: 1.033 mg (equivalent: estradiol, qty 1 mg); drospirenone, quantity: 2 mg - tablet, film coated - excipient ingredients: povidone; hypromellose; magnesium stearate; lactose monohydrate; purified talc; macrogol 6000; titanium dioxide; pregelatinised maize starch; maize starch; iron oxide red - hormone replacement therapy (hrt) for use in the short-term treatment in postmenopausal women with an intact uterus of the climacteric syndrome caused by deficient endogenous oestrogen production due to natural menopause, hypogonadism, castration or primary ovarian failure.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 2.07 mg (equivalent: estradiol, qty 2 mg); norethisterone acetate, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; hyprolose; purified talc; magnesium stearate; hypromellose; triacetin - short term symptomatic treatment of oestrogen deficiency associated with natural or artificial menopause (see dosage and administration and clinical trials).

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 2.07 mg (equivalent: estradiol, qty 2 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; purified talc; magnesium stearate; titanium dioxide; hypromellose; hyprolose; indigo carmine; macrogol 400 - short term symptomatic treatment of oestrogen deficiency due to natural or surgical menopause in hysterectomised postmenopausal women. in women with intact uteri, use of opposed therapy must be considered.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 1.03 mg (equivalent: estradiol, qty 1 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; purified talc; magnesium stearate; titanium dioxide; hypromellose; hyprolose; iron oxide red; propylene glycol - short term symptomatic treatment of oestrogen deficiency due to natural or surgical menopause in hysterectomised postmenopausal women. in women with intact uteri, use of opposed therapy must be considered.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - dydrogesterone, quantity: 10 mg; estradiol, quantity: 2 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; colloidal anhydrous silica; lactose monohydrate; maize starch; titanium dioxide; purified talc; iron oxide yellow; macrogol 400 - hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uterus. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used with the goal being short term use (see dosage and administration and clinical trials). when prescribed solely for the prevention of postmenopausal bone mineral density loss in women, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of femoston should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing( see precautions and dosage and administration).

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - estradiol hemihydrate, quantity: 2.06 mg (equivalent: estradiol, qty 2 mg) - tablet, film coated - excipient ingredients: maize starch; hypromellose; colloidal anhydrous silica; lactose monohydrate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; iron oxide black; macrogol 400 - symptomatic treatment of oestrogen deficiency due to natural or surgical menopause in hysterectomised post menopausal women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used with the goal being short term use. in women with an intact uteri, use of opposed therapy must be considered.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - estriol, quantity: 1 mg - tablet, uncoated - excipient ingredients: amylopectin; potato starch; lactose monohydrate; magnesium stearate - short-term treatment of menopausal syndrome. review the need for continuation of treatment after 6 months treatment, taking into account the risk-benefit ratio for the individual user at that moment (including cardiovascular disease and breast cancer, refer to clinical trials and precautions). ovestin tablets should only be continued for as long as the benefit outweighs the risks.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

bioactive laboratories pty ltd - colecalciferol, quantity: 1.25 microgram (equivalent: colecalciferol, qty 50 iu); khaya senegalensis, quantity: 500 mg (equivalent: khaya senegalensis, qty 500 mg); calcium carbonate, quantity: 250 mg (equivalent: calcium, qty 100.1 mg) - tablet, film coated - excipient ingredients: dl-alpha-tocopherol; povidone; maize oil; croscarmellose sodium; magnesium stearate; crospovidone; macrogol 6000; colloidal anhydrous silica; ascorbic acid; microcrystalline cellulose; macrogol 400; hypromellose; dextrin; glyceryl monostearate; sucrose - traditionally used in western herbal medicine to relieve weariness/tiredness/fatigue/feeling of weakness ; a diet deficient in calcium can lead to osteoporosis in later life. calcium may help prevent osteoporosis when dietary intake is inadequate ; vitamin d helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life ; traditionally used in western herbal medicine to decrease/reduce/relieve abdominal spasm ; traditionally used in western herbal medicine to helps reduce occurrence of abdominal spasm ; traditionally used in western herbal medicine to decrease/reduce/relieve symptoms of heartburn ; traditionally used in western herbal medicine to decrease/reduce/relieve gastrointestinal pain ; traditionally used in western herbal medicine to decrease/reduce/relieve symptoms of mild anxiety ; traditionally used in western herbal medicine to relieves mid-cycle menstrual pain ; traditionally used in western herbal medicine to maintain/support/regulate healthy menstrual cycle ; traditionally used in western herbal medicine to decrease/reduce/relieve menstrual spasms/cramps ; traditionally used in western herbal medicine to decrease/reduce heavy menstruation/periods ; traditionally used in western herbal medicine to decrease/reduce/relieve menstruation pain/dysmenorrhoea ; traditionally used in western herbal medicine to decrease/reduce feelings of aggression/irritability associated with premenstrual tension ; traditionally used in western herbal medicine to decrease/reduce/relieve mood changes/mood swings associated with premenstrual tension ; traditionally used in western herbal medicine to decrease/reduce/relieve breast pain/tenderness associated with premenstrual tension ; traditionally used in western herbal medicine to help decrease/reduce/relieve confusion associated with premenstrual tension/syndrome ; traditionally used in western herbal medicine to decrease/reduce/relieve symptoms of premenstrual tension ; traditionally used in western herbal medicine to helps reduce occurrence of premenstrual tension symptoms ; traditionally used in western herbal medicine to helps reduce occurrence of menopausal symptoms